On Feb. 26, 2016, applied by St. Stamford Modern Cancer Hospital Guangzhou, the research project comparing efficacy and safety between treatments of combining nanoknife with gemcitabine and radiotherapy with gemcitabine for local pancreatic cancer, was approved by Guangzhou Health and Family Planning Commission. In the afternoon of Dec. 5 St. Stamford Modern Cancer Hospital Guangzhou gave the opening report of the research project with the participation and guidance of Prof. Xu Meng, chief physician and doctoral supervisor of the first clinical medicine college of Jinan University and organizer of biological treatment committee of Guangdong anticancer association, and presence of Tu Xiaoming, vice president of Singapore St.Stamford International Medical Group, and Wang Huaizhong, dean of St. Stamford Modern Cancer Hospital Guangzhou, together with other leaders and research groups.
Members of the research project initiation consultation committee
In the ceremony, Huang Deliang, oncology inpatient department director of St. Stamford Modern Cancer Hospital Guangzhou, gave the theme report to the project comparing efficacy and safety between treatments of combining nanoknife with gemcitabine and radiotherapy with gemcitabine. The subject of the research is to compare the local ablation efficacy of nanoknife, when combined with current well-acknowledged effective treatment of gemcitabine, with combination of gemcitabine with other therapies, and assess their safety to serve better clinical application. This project is, verified by Guangzhou intelligence institute, an initiative research project at home and abroad and also a breakthrough in pancreatic cancer treatment.
Huang Deliang, executor of the research project
Then the research group held a heated discussion over main content and feasibility of the research, focusing on the expected effect of combining gemcitabine with nanoknife technology at its 100% efficacy in treating pancreatic cancer. Associated director of oncology department and doctoral supervisor, Prof. Wang Xin, pointed out, as long as pancreatic cancer patients treated by the joint treatment of nanoknife and gemcitabine survive longer than the control group, the research is testified successful, so just keep calm during the process. Meanwhile, the research group also conducted analysis and discussion on every detail of the research process to guarantee the final success.
On the scene of the opening ceremony of the research project
In the end, Prof. Xu Meng gave his comments and instruction on the research project, which according to him is research on precision medicine and ranks in advanced research fields. He stressed study index detailing and safety during the research, expecting a formation of the hospital’s own clinical treatment guidelines based on 30 cases of joint treatment of nanoknife and gemcitabine. He hoped the research group can steadily conducts this project, with high-end technology of nanoknife as a platform and pancreatic cancer treatment as a start, to establish a characteristic treatment of high-end nanoknife technology combined with other therapies. He believed, with pancreatic cancer as the first target, it will cover more cancers and benefit more cancer patients.
Tu Xiaoming, Vice president of Singapore St.Stamford International Medical Group
During the opening report, Tu Xiaoming, Vice president of Singapore St.Stamford International Medical Group, said it’s not easy to get the government's approval for a research project, but St.Stamford Modern Cancer Hospital Guangzhou has successfully passed two research project initiations. Besides the mentioned project, the other one was research on the feasibility of cryotherapy in triple-negative breast cancer recurrence and metastasis, applied by director Dai Wenyan. These indicated the hospital’s new level in technical innovation and overall improvement on academic and research ability. The opening report aroused extensive social attention.